Ponatinib Treatment in CML and Ph plus ALL Patients: Real-Life Data from the Czech Registries

被引：0
|
作者：
Koritakova, Eva
Doubek, Michael
Faber, Edgar
Zackova, Daniela
Horacek, Jan M.
Belohlavkova, Petra
Cmunt, Eduard
Folber, Frantisek
Jindra, Pavel
Klamova, Hana
Koristek, Zdenek
Stejskal, Lukas
Szotkowski, Tomas
Salek, Cyril
Kellnerova, Renata
Chrapava, Marika
机构：
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5905
引用
收藏
页数：3
相关论文
共 50 条
  • [41] THE 8-YEAR RETENTION RATE OF THE FIRST TNF-INHIBITOR IN THE TREATMENT OF SPONDYLOARTHROPATHIES: REAL-LIFE DATA FROM A MULTICENTRIC LOCAL REGISTRIES
    Favalli, E. G.
    Selmi, C.
    Becciolini, A.
    Biggioggero, M.
    Ariani, A.
    Santilli, D.
    Fusaro, E.
    Parisi, S.
    Massarotti, M.
    Marchesoni, A.
    Meroni, P. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 810 - 810
  • [42] The 8-Year Retention Rate of the First TNF-Inhibitor in the Treatment of Spondyloarthropathies: Real-Life Data from Three Local Registries
    Favalli, Ennio Giulio
    Becciolini, Andrea
    Biggioggero, Martina
    Fusaro, Enrico
    Parisi, Simone
    Ariani, Alarico
    Santilli, Daniele
    Marchesoni, Antonio
    Meroni, Pier Luigi
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [43] Tyrosine Kinase Inhibitor (TKI) Discontinuation in Non-Allografted Ph plus Acute Lymphoblastic Leukemia Patients, a Campus ALL Real-Life Study
    Dragani, Matteo
    Agrippino, Roberta
    Cambrin, Giovanna Rege
    Leoncin, Matteo
    Cerrano, Marco
    Salutari, Prassede
    Mule, Antonino
    Papayannidis, Cristina
    Defina, Marzia
    Rivoli, Giulia
    Todisco, Elisabetta
    Abruzzese, Elisabetta
    Cedrone, Michele
    Fracchiolla, Nicola
    Guolo, Fabio
    Lanzarone, Giuseppe
    Foa, Robin
    Chiaretti, Sabina
    BLOOD, 2023, 142
  • [44] Use of Ponatinib Alone or Combined with Other Therapies in Relapsed/Refractory Ph-like Acute Lymphoblastic Leukemia. a Campus ALL Real-Life Study
    Lunghi, Monia
    Kaiser, Francesca
    Cardinali, Deborah
    Basilico, Claudia
    Defina, Marzia
    Mastaglio, Sara
    Davide, Lazzarotto
    Salutari, Prassede
    Piccini, Matteo
    Cardinali, Valeria
    Pierini, Antonio
    Fracchiolla, Nicola
    Di Biase, Federica
    Annunziata, Mario
    Di Trani, Mariangela
    Ferrara, Felicetto
    Pizzolo, Giovanni
    Foa, Robin
    Chiaretti, Sabina
    BLOOD, 2023, 142
  • [45] Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph plus ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820
    Chiaretti, Sabina
    Leoncin, Matteo
    Elia, Loredana
    Soddu, Stefano
    Piciocchi, Alfonso
    Matarazzo, Mabel
    Di Trani, Mariangela
    Martelli, Maurizio
    Borlenghi, Erika
    Parisi, Marina
    Mancini, Valentina
    Alati, Caterina
    Mattei, Daniele G.
    Martelli, Maria Paola
    Salutari, Prassede
    Chiusolo, Patrizia
    Audisio, Ernesta
    Luppi, Mario
    Pochintesta, Lara
    Pasciolla, Crescenza
    Serio, Bianca
    Scappini, Barbara
    Cucca, Antonella
    Chiarucci, Martina
    Bonifacio, Massimiliano
    Fracchiolla, Nicola
    Imbergamo, Silvia
    Ammirati, Lucia
    Mosna, Federico
    Zappasodi, Patrizia
    Mastaglio, Sara
    Pietrasanta, Daniela
    Bocchia, Monica
    Lunghi, Monia
    Todisco, Elisabetta
    Fazi, Paola
    Rambaldi, Alessandro
    Foa, Robin
    BLOOD, 2024, 144 : 835 - 837
  • [46] PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph plus ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    Paquette, Ronald
    le Coutre, Philipp D.
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane
    Khoury, Hanna Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Rea, Delphine
    Abruzzese, Elisabetta
    Mueller, Martin C.
    Baccarani, Michele
    Gambacorti-Passerini, Carlo
    Turner, Christopher D.
    Haluska, Frank G.
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
    Gkalpakiotis, Spyridon
    Cetkovska, Petra
    Arenberger, Petr
    Dolezal, Tomas
    Arenbergerova, Monika
    Velackova, Barbora
    Fialova, Jorga
    Kojanova, Martina
    DERMATOLOGY AND THERAPY, 2021, 11 (04) : 1345 - 1355
  • [48] Registry data from Sweden Real-life data on urticaria
    Lux, Sebastian
    ALLERGO JOURNAL, 2022, 31 (05) : 8 - 8
  • [49] Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
    Spyridon Gkalpakiotis
    Petra Cetkovska
    Petr Arenberger
    Tomas Dolezal
    Monika Arenbergerova
    Barbora Velackova
    Jorga Fialova
    Martina Kojanova
    Dermatology and Therapy, 2021, 11 : 1345 - 1355
  • [50] REAL-LIFE DATA FROM 180 CONSECUTIVE PATIENTS UNDERGOING AQUABLATION OF THE PROSTATE
    Bach, Thorsten
    Giannakis, Iannis
    Karimi, Magdalena
    Rijo, Enrique
    JOURNAL OF UROLOGY, 2019, 201 (04): : E640 - E641
12345